FDY 5301

Drug Profile

FDY 5301

Alternative Names: FDY-5301

Latest Information Update: 28 Sep 2016

Price : $50

At a glance

  • Originator Faraday Pharmaceuticals
  • Class Reducing agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Reperfusion injury

Most Recent Events

  • 23 Sep 2016 Phase-I clinical trials in Reperfusion injury in Australia (IV) (ACTRN12616001165471)
  • 07 Sep 2016 Faraday plans a phase I trial for Reperfusion injury in Australia (ACTRN12616001165471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top